Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Down .43 off the high

<< Previous

Bullboard Posts

Next >>

Comment by wethenorthhon Dec 01, 2021 4:28pm

106 Views

Post# 34187115

RE:Down .43 off the high

It's best to get rid of these weak hands right now, who are selling for beer and peanuts, then later on.

I believe once people fully understand the news release and see how insane this news actually is, we will start flying. Was better then I even expected!

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading